18:23 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; brain cancer; solid tumors Mouse studies suggest liposomal nanoparticles loaded with immunomodulatory agents could enhance the efficacy of CAR T therapies to treat solid cancers. The liposomal nanoparticles are coated with an integrin...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis as...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Glioblastoma Epidermal growth factor receptor variant III (EGFRvIII); prominin 1 (PROM1; CD133)...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In...
01:03 , May 19, 2011 |  BC Extra  |  Financial News

Celldex raises $31.5 million

Celldex Therapeutics Inc. (NASDAQ:CLDX) raised $31.5 million through the sale of 10 million shares at $3.15 per share in a follow-on underwritten by Jefferies; Wedbush; Brean Murray; and Roth Capital Partners. The offering was proposed...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

Rindopepimut: Final Phase IIb data

Final data from the single-arm, open-label Phase IIb ACT III trial in 65 patients showed that rindopepimut plus granulocyte-macrophage colony-stimulating factor (GM-CSF) met the primary endpoint of significantly improving the rate of PFS at 5.5...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

Rindopepimut: Phase II data

A U.S. Phase II trial in 35 patients with newly-diagnosed GBM showed that rindopepimut plus standard of care (SOC) significantly improved median PFS vs. SOC alone (14.2 vs. 6.3 months, p=0.013). Rindopepimut plus SOC also...
07:00 , Aug 12, 2010 |  BC Innovations  |  Tools & Techniques

Dendritic cell dragnet

The inability of peripheral immune cells to penetrate the CNS protects the brain against inflammation but has thwarted efforts to stimulate immunity against brain cancer antigens. Now a team at Cedars-Sinai Medical Center has devised...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Clinical News

Rindopepimut: Interim Phase IIb data

Interim data from the ongoing, open-label, U.S. Phase IIb ACT III trial in 40 evaluable patients treated with rindopepimut showed that 70% of patients were progression-free at 5.5 months. Patients received rindopepimut biweekly for 3...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

Qiagen, Pfizer deal

Pfizer and Qiagen's DxS subsidiary partnered to develop a companion diagnostic for Pfizer's cancer vaccine PF-04948568 ( CDX-110). The vaccine targeting epidermal growth factor receptor variant III ( EGFRvIII) is in Phase II...